FDA Approves Gemtuzumab Ozogamicin for CD33+ Pediatric AML
The US Food and Drug Administration has extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly-diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.